Vyvgart Hytrulo CIDP denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Vyvgart Hytrulo for CIDP as Experimental

Blue Cross Blue Shield may classify a treatment as experimental or investigational when its internal medical-policy review has not yet incorporated the most recent regulatory and clinical developments, or when a specific formulation or delivery route — such as the subcutaneous co-formulation with hyaluronidase — is evaluated separately from the intravenous formulation. Vyvgart Hytrulo received FDA approval for its CIDP indication, but BCBS plan policies update on a lag, and some plan variants continue to flag the subcutaneous formulation under older experimental criteria that predate the approval or that have not been updated to reflect current guideline recognition.

## Why This Denial Is Appealable

FDA approval is the primary regulatory threshold for establishing that a treatment is not experimental. When a plan's internal experimental classification contradicts current FDA labeling, that conflict is exactly what independent external review is designed to resolve. Professional society guidelines from organizations such as the American Academy of Neurology and the Peripheral Nerve Society that recognize the treatment as standard of care for CIDP provide additional weight. A well-documented appeal that leads with the FDA approval and follows with current society guidance positions the case strongly for both internal and external review.

## Federal Appeal Framework

• Internal appeal — file within the deadline on your denial notice (typically 180 days); attach the FDA label as Exhibit A.
• External review (ACA §2719) — after a final internal denial on a fully-insured BCBS plan, you have approximately four months to request independent review by an accredited organization; experimental-treatment denials are a core category reviewers are empowered to overturn.
• ERISA §503 — self-funded employer plans must provide a full-and-fair review; the plan must specify which evidence criteria the drug failed and why FDA approval did not satisfy those criteria.
• Expedited track — strongly recommended given the progressive nature of untreated CIDP.

## Documentation to Gather

1. FDA prescribing label (current) — confirming approval for the CIDP indication, with relevant sections highlighted. 2. CIDP diagnosis and disease-course records — neurology documentation showing diagnosis, progression, and current functional status. 3. Prior-treatment history — documentation of prior CIDP treatments, responses, and reasons for transition to Vyvgart Hytrulo. 4. Professional society guideline references — a prescriber letter referencing recognized neurology society guidance that supports subcutaneous FcRn antagonism as an established treatment for CIDP. 5. Prescriber medical-necessity and non-experimental attestation — a letter from the treating neurologist stating that this treatment is consistent with current standards of care and is not experimental for the patient's confirmed diagnosis.

## Criteria-Mapping Structure

Obtain BCBS's experimental/investigational policy and any specific policy covering Vyvgart Hytrulo or FcRn antagonists in CIDP. For each criterion the plan uses to define experimental status, place the criterion on the left and the responsive documentation on the right. Lead with the FDA approval fact — it is the single strongest rebuttal — and follow with the professional-society recognition and the treating neurologist's attestation that this is standard-of-care treatment for this patient's confirmed, documented condition.